MLYS

Business Context and Reporting Period

Company: Mineralys Therapeutics, Inc. (MLYS)
Reporting Period: Quarter ended March 31, 2026 (Form 10-Q)
Business Overview: A biopharmaceutical company developing lorundrostat, an aldosterone synthase inhibitor for hypertension and related comorbidities. The company submitted a New Drug Application (NDA) to the FDA in December 2025 with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

Key Financial Metrics

Note: The filing does not provide a specific "margin" metric as the company has no revenue. Liquidity is defined by cash, cash equivalents, and investments totaling $646.1 million as of March 31, 2026.

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by $2.9 million (6.8%) compared to Q1 2025, driven by a reduction in operating expenses and increased interest income.
• Research & Development (R&D): R&D expenses decreased by $13.5 million to $24.4 million. This was primarily due to a $15.5 million reduction in preclinical and clinical costs following the conclusion of the pivotal lorundrostat program in Q2 2025.
• General & Administrative (G&A): G&A expenses increased significantly by $14.4 million to $21.0 million. This increase was driven by higher professional fees ($7.9 million) and personnel-related expenses ($6.1 million) as the company builds pre-commercial capabilities.
• Interest Income: Interest income increased by $3.8 million to $6.0 million, reflecting higher average cash balances invested in money market funds and U.S. Treasuries.
• Capital Raise: The company raised approximately $20.2 million in net proceeds through its At-The-Market (ATM) offering during Q1 2026. In Q1 2025, the company raised approximately $189.2 million via a public offering.

Outlook, Risks, and Management Commentary

• Regulatory Status: The FDA accepted the NDA for lorundrostat for hypertension. The PDUFA target date is December 22, 2026. Management expects to incur substantial costs related to regulatory activities and commercial launch preparations.
• Clinical Updates: Topline data from the Phase 2 Explore-OSA trial (Obstructive Sleep Apnea) announced March 9, 2026, showed lorundrostat did not meet the primary endpoint (apnea-hypopnea index) but demonstrated a clinically meaningful reduction in blood pressure.
• Liquidity: Management believes current cash, cash equivalents, and investments ($646.1 million) are sufficient to fund operations for at least 12 months from the filing date.
• Risks: Key risks include the uncertainty of FDA approval, the need for additional capital to fund commercialization, potential dilution from future equity offerings, and the contingent milestone and royalty obligations under the Tanabe License Agreement (up to $155 million in commercial milestones).
• Unusual Items: No unusual items were reported. The company continues to operate as an emerging growth company and smaller reporting company.

Investor Verification Checklist

• NDA Review Status: Verify the status of the FDA review for the lorundrostat NDA submitted in December 2025 and any potential requests for additional information.
• Cash Burn Rate: Monitor the quarterly cash burn rate against the $646.1 million liquidity position to assess the runway for commercialization.
• Commercial Milestones: Review the Tanabe License Agreement terms regarding the $155 million in potential commercial milestone payments and royalty obligations.
• ATM Utilization: Track the remaining capacity under the ATM agreement ($187.2 million available as of March 31, 2026) and the weighted average price of shares sold.
• Expense Trajectory: Monitor the trend of G&A expenses as the company transitions from a pure R&D phase to pre-commercial operations.